Tejaswini Reddy

Abstract Metaplastic breast cancer (MpBC) is a highly chemoresistant subtype of breast cancer with no standardized therapy options. A clinical study in anthracycline-refractory MpBC patients suggested that nitric oxide synthase (NOS) inhibitor NG-monomethyl-l-arginine (L-NMMA) may augment anti-tumor efficacy of taxane. We report that NOS blockade potentiated response of human MpBC cell lines and tumors to phosphoinositide 3-kinase (PI3K) inhibitor alpelisib and taxane.

SHORT COMMUNICATION Akshjot Puri MD Corresponding Author apuri@houstonmethodist.org orcid.org/https://orcid.org/0000-0001-7187-7561 Houston Methodist Cancer Center, Houston, Texas, USA Correspondence Akshjot Puri, Houston Methodist Cancer Center, 6445 Main St, Houston, TX 77030. Email: apuri@houstonmethodist.org Search for more papers by this author PDF ShareShare Abstract Metastatic triple‐negative breast cancer (mTNBC) patients tend to have a poor overall survival.

Abstract Metaplastic breast cancer (MpBC) is an exceedingly rare breast cancer variant that is therapeutically challenging and aggressive. MpBC is defined by the histological presence of at least two cellular types, typically epithelial and mesenchymal components. This variant harbors a triple-negative breast cancer (TNBC) phenotype, yet has a worse prognosis and decreased survival compared to TNBC. There are currently no standardized treatment guidelines specifically for MpBC.